natgillin/translations-raw huggingface dataset:
Tell your doctor, pharmacist or nurse straight away if you notice any of the following serious side effects - you may need urgent medical treatment: - nausea or vomit (feeling or being sick), diarrhoea - signs of liver problems - these include yellowing of your skin or whites of the eyes, unusually dark urine or pale faeces, feeling sick for no reason, stomach problems, loss of appetite or unusual tiredness or weakness, an increase in liver enzymes shown up in blood tests - allergic reaction. 
- znakitežav z jetri;mednjimi so porumenelost kože ali očesnih beločnic, nenavadno temen urinali svetlo blato, slabost v želodcu brez razloga, težave z želodcem, izguba apetita ali nenavadna utrujenost ali šibkost, zvišanje jetrnih encimov (pokaže se na preiskavah krvi) - alergijska reakcija
Tell your doctor if you are or think you are pregnant before you start to take Posaconazole AHCL. 
Če ste noseči ali menite, da bi lahko bili noseči, se posvetujte z zdravnikom, preden vzamete zdravilo Posakonazol AHCL.
The recommended dose is 200 mg (one 5 mL spoonful) taken four times daily. 
Priporočeniodmerek je 200 mg (ena polna 5 ml žlička)štirikratna dan.
Pulmonary phospholipidosis resulting in dilatation and obstruction of the alveoli was observed in the 2-year study in rats. 
V2-letništudijina podganah so opažali pljučno fosfolipidozo, ki je povzročila dilatacijo inobstrukcijo alveolov.
If you get any side effects, talk to your doctor, pharmacist or nurse. 
Če opazite kateregakoliizmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom alimedicinsko sestro.
Similarly, administration of 400 mg posaconazole with esomeprazole (40 mg daily) decreased mean Cmax and AUC by 46 % and 32 %, respectively, compared to dosing with 400 mg posaconazole alone. 
Podobno staseprijemanju 400 mg posakonazola z esomeprazolom (40 mg na dan) v primerjavi zjemanjemsamega posakonazola v odmerku 400 mgzmanjšalisrednja vrednost Cmaxoz.
If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood. 
Če se sočasniuporabi ni mogoče izogniti, je ob uvedbi zdravljenja s posakonazolompriporočljivo zelozmanjšatiodmereksirolimusainzelopogosto preverjatinajnižjo koncentracijo sirolimusa v polnikrvi.
Uncommon: the following may affect up to 1 in 100 people - anaemia - signs include headaches, feeling tired or dizzy, being short of breath or looking pale and a low level of haemoglobin shown up in blood tests - low level of platelets (thrombocytopenia) shown in blood tests - this may lead to bleeding - low level of “leukocytes” a type of white blood cell (leukopenia) shown in blood tests - this can make you more likely to get infections - high level of “eosinophils” a type of white blood cell (eosinophilia) - this can happen if you have inflammation - inflammation of the blood vessels - heart rhythm problems 
- anemija - med znaki so glavoboli, utrujenost ali omotičnost, kratka sapa ali bledica ter nizka koncentracija hemoglobina, ki se pokaže na preiskavah krvi - nizko število trombocitov (trombocitopenija), ki se pokaže na preiskavah krvi - povzroči lahko krvavitve - nizko število levkocitov - belih krvnih celic (levkopenija) - pokaže se na preiskavah krvi;
Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively. 
Po 7-dnevnisočasni uporabi peroralne suspenzije posakonazola(400 mgdvakrat na dan) z atazanavirjem in ritonavirjem (300/100 mg enkrat na dan) seje pri zdravihpreiskovancih Cmaxatazanavirjapovečala v povprečju za1,5-krat,njegovaAUC paza 2,5-krat (razponod 0,9-kratdo 4,1-krat).
Monitoring of glucose concentrations is recommended in diabetic patients. 
Pri sladkornih bolnikih jepriporočljivospremljatikoncentracije glukoze.
Neuronal phospholipidosis occurred in dogs dosed for ≥ 3 months at lower systemic exposures than those obtained at therapeutic doses in humans. 
Pri psih, ki so ≥3 mesecedobivaliodmerke zdravila za manjšo sistemsko izpostavljenost od tiste,dosežene med uporabo terapevtskih odmerkov pri človeku, se je pojavila fosfolipidoza nevronov.
If you become pregnant while you are taking Posaconazole AHCL, contact your doctor straight away. 
Če med jemanjem zdravila Posakonazol AHCL zanosite, se nemudoma posvetujte z zdravnikom.
Frequent monitoring for adverse reactions and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole. 
Medsočasnouporabo s posakonazolom jepriporočljivo pogosto spremljanje gledeneželenih učinkovin toksičnosti, povezanih z zaviralci kalcijevih kanalčkov.
In general, exposures tended to be higher in the older patients (7 to <18 years) than in younger patients (2 to <7 years). 
dan med 500 ng/mlin 2.500 ng/ml).Nasplošnoso bile izpostavljenosti večinoma višjepristarejšihbolnikih(7 do < 18 let) kot pri mlajših bolnikih (2 do < 7 let).
- fits (convulsions) - nerve damage (neuropathy) - abnormal heart rhythm - shown up on a heart trace (ECG), palpitations, slow or fast heartbeat, 
- motnje srčnega ritma - pokažejo se na zapisu električnega delovanja srca (EKG), razbijanje srca
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function. 
Po enkratnem peroralnem odmerku 400 mg peroralne suspenzije posakonazola pri bolnikih z blago (razred A po Child-Pughu), zmerno (razred B po Child-Pughu) ali hudo okvaro jeter (razred C po
Due to the risk of prolonged sedation it is recommended that dose adjustments should be considered when posaconazole is administered concomitantly with any benzodiazepine that is metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) (see section 4.4). 
Zaradi tveganja zadolgotrajnejšosedacijo je v primeru sočasne uporabe posakonazolainkateregakolibenzodiazepina, ki se presnovis CYP3A4 (npr. midazolama, triazolama ali alprazolama), priporočljivo razmisliti o prilagoditviodmerka (glejte poglavje 4.4).
b: In 1899 this was the period from randomization to last dose of study medicinal product plus 7 days; in 316 
Vštudiji1899jebilotoobdobje od randomizacije do zadnjega odmerka preučevanega zdravilaplus7 dni, v študiji316 pa je bilo to obdobje od prvega odmerka do zadnjega odmerka preučevanega zdravila plus 7dni.
Repeat dose administration of posaconazole oral suspension (400 mg twice daily for 16 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 6.7-fold and 8.9-fold (range 3.1 to 17.5-fold), respectively, in healthy subjects. 
Uporabavečkratnih odmerkovposakonazola vobliki peroralne suspenzije (400 mg dvakrat na dan16 dni) jepri zdravihosebah (kiso dobile enkraten odmerek2 mgsirolimusa) povečala Cmaxsirolimusa v povprečjuza 6,7-kratin AUCsirolimusa v povprečju za 8,9-krat (razpon od 3,1-kratdo17,5-krat).
After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose). 
Posakonazolse izloča počasi, s srednjo razpolovno dobo (t½) 35 ur (razpon od 20 do 66 ur).Pouporabi 14C-posakonazola se jeradioaktivnost pojavila predvsem v blatu(77 % radioaktivnooznačenega odmerka);glavnidel tega jebila matična spojina (66% radioaktivnooznačenegaodmerka).
Following co-administration of posaconazole oral suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold), respectively. 
Po 7-dnevnisočasni uporabi peroralne suspenzijeposakonazola(400 mg dvakrat na dan) z atazanavirjem (300 mg enkrat na dan) seje pri zdravihpreiskovancih Cmaxatazanavirjapovečala v povprečju za2,6-krat,njegovaAUC paza 3,7-krat (razponod 1,2-kratdo 26-krat).
• If you get any side effects, talk to your doctor or pharmacist. 
• Če opazite katerikoli neželeni učinek, seposvetujte z zdravnikom alifarmacevtom.
Talk to your doctor or pharmacist before taking Posaconazole AHCL - if you have had an allergic reaction to another antifungal medicine such as ketoconazole, 
- če ste imeli alergijsko reakcijo na kakšno drugo protiglivno zdravilo, npr. na ketokonazol,
Phenytoin (200 mg once a day) decreased the Cmax and AUC of posaconazole by 41 % and 50 %, respectively. 
Fenitoin(200 mg enkrat na dan) je zmanjšalCmaxposakonazola za 41 %, njegovoAUC paza 50 %.Sočasni uporabi posakonazola in fenitoina ter podobnih induktorjev (npr.
In subjects with severe renal impairment (n=6, Cl cr< 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV]. 
Pripreiskovancih s hudookvaro ledvic (n = 6, očistek kreatinina< 20 ml/min/1,73 m2) je bila AUC posakonazola močno spremenljiva
Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole. 
Medsočasno uporabo posakonazola je priporočljivo pogosto spremljanje glede neželenih učinkovintoksičnosti, povezanih s protiretrovirusnimizdravili, ki so substrati CYP3A4.
STATEMENT OF ACTIVE SUBSTANCE(S) Each mL contains 40 mg of posaconazole. 
En ml vsebuje 40 mg posakonazola.
Stevens Johnson syndrome, vesicular rash Musculoskeletal and connective tissue disorders Uncommon: 
Stevens-Johnsonov sindrom, vezikularen izpuščaj
How to take Posaconazole AHCL 
Kako jemati zdravilo Posakonazol AHCL
In both prophylaxis studies, aspergillosis was the most common breakthrough infection. 
V obeh študijah profilaktične uporabe zdravila je bila aspergiloza najpogostejša prebijajočaokužba.Za izsledke obeh študij glejte preglednici 5 in 6.
No effects on electrocardiograms, including QT and QTc intervals, were seen in a repeat dose safety pharmacology study in monkeys at systemic exposures 4.6-fold greater than the concentrations obtained at therapeutic doses in humans. 
Vfarmakološki študijivarnosti ponavljajočihse odmerkov na opicah pri sistemskih izpostavljenostih,ki so bile 4,6-krat večje od koncentracij, doseženih med uporabo terapevtskihodmerkovpričloveku,na elektrokardiogramih (vključno z intervaloma QT in QTc) niso opazili nobenih učinkov.
NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension posaconazole 
Navodilo za uporabo Posakonazol AHCL 40 mg/ml peroralna suspenzija posakonazol
The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period. 
Primarni opazovani dogodekučinkovitosti je bila pojavnostdokazanih oziroma verjetnih invazivnihglivnihokužb,kijihje ugotavljala neodvisna skupina zunanjih strokovnjakov na slep način medobdobjemzdravljenja.Ključnisekundarni opazovani dogodekjebila pojavnostdokazanihoziromaverjetnih invazivnihglivnihokužb 100 dni po randomizaciji.
In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively. 
V drugi študiji pri zdravih prostovoljcih je uporaba večkratnih odmerkovperoralne suspenzijeposakonazola (200 mg dvakrat na dan7dni) povečala Cmaxintravenskouporabljenega midazolama(enkratni odmerek0,4 mg) v povprečju za 1,3-krat,njegovoAUC pa za 4,6-krat (razpon od 1,7-kratdo 6,4-krat).
Oral posaconazole suspension 800 mg/day in divided doses was evaluated for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a noncomparative salvage therapy trial (Study 0041). 
Vneprimerjalnem preskušanju (študija 0041) zadnje možnosti zdravljenja so za zdravljenje invazivneaspergilozepribolnikih z okužbo,odpornonaamfotericin B (vključno z liposomskimioblikami)aliitrakonazol,oziroma pri bolnikih, ki niso prenašali teh zdravil, ovrednotili peroralno suspenzijoposakonazola 800 mg/dan v deljenih odmerkih.
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4. 
Zaviralci reduktaze HMG-CoA, ki se presnovijo s CYP3A4 (npr. simvastatin, lovastatin inatorvastatin) Posakonazollahko bistveno povečaplazemsko koncentracijo zaviralcev reduktaze HMG-CoA, ki sepresnovijo s CYP3A4.
First time treatment of Thrush 
Prvo zdravljenje sora
which are given with ritonavir) - midazolam, triazolam, alprazolam or other “benzodiazepines” (used as sedatives or muscle relaxants) - diltiazem, verapamil, nifedipine, nisoldipine or other “calcium channel blockers” (used to treat high blood pressure) - digoxin (used to treat heart failure) - Glipizide or other “sulfonylureas” (used to treat high blood sugar). 
- diltiazem, verapamil, nifedipin, nizoldipinin drugi zaviralci kalcijevih kanalčkov (uporabljajose za zdravljenje visokega krvnega tlaka),
Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomization, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P= 0.0354) as well as IFI-related deaths (P = 0.0209). 
Ta koristen vpliv na preživetje so dokazali, ko so vanaliziupoštevalivsevzrokesmrti(p = 0,0354), pa tudi smrti, povezane z invazivno glivno okužbo(p
Do not breast-feed while taking Posaconazole AHCL. 
Ne jemljite zdravila Posakonazol AHCL:
How to store Posaconazole AHCL Contents of the pack and other information 
Izgled zdravila Posakonazol AHCL in vsebina pakiranja
hepatocellular damage, hepatitis, jaundice, hepatomegaly, cholestasis, hepatic toxicity, hepatic function abnormal 
okvara jetrnih celic, hepatitis, zlatenica, hepatomegalija, holestaza,
Each dose of Posaconazole AHCL should be administered during or immediately after a meal, or a nutritional supplement in patients who cannot tolerate food to enhance the oral absorption and to ensure adequate exposure. 
Bolniki, ki ne prenašajohrane, naj zdravilo vzamejo med ali takoj po zaužitju prehranskegadodatka, da bi povečali peroralno absorpcijo in zagotovili zadostno izpostavljenost zdravilu.
c: In 1899, this was the period from randomization to 100 days post-randomization; in 316 it was the period from the baseline day to 111 days post-baseline. 
Vštudiji1899jebilotoobdobje od randomizacije do zadnjega odmerka preučevanega zdravilaplus7 dni, v študiji316 pa je bilo to obdobje od prvega odmerka do zadnjega odmerka preučevanega zdravilaplus7dni.
These medicines include: - vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer) - ciclosporin (used during or after transplant surgery) - tacrolimus and sirolimus (used during or after transplant surgery) - rifabutin (used to treat certain infections) - medicines used to treat HIV called protease inhibitors (including lopinavir and atazanavir, 
- rifabutin(uporabljase za zdravljenje določenih okužb), - zdravila za zdravljenje HIV,imenovana zaviralci proteaz (vključno z lopinavirjem inatazanavirjem, ki se dajetaskupaj zritonavirjem), - midazolam, triazolam, alprazolam indrugi benzodiazepini (uporabljajo se kot pomirjevala alizdravila za sprostitev mišic),
Concomitant use of posaconazole and efavirenz should be avoided unless the benefit to the patient outweighs the risk. 
karbamazepina,fenobarbitala, primidona)se je treba izogibati, razen če korist za bolnika odtehta tveganje.
The table below shows the recommended dose and length of treatment which depend on the type of infection that you have and may be individually adapted for you by your doctor. 
Spodnja preglednica prikazuje priporočeni odmerek intrajanjezdravljenja gledenavrstookužbe, kijoimate.Zdravnikvamlahkoodmerekintrajanjezdravljenja individualno prilagodi.
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed. 
Posakonazol v obtoku nima nobenega glavnega presnovka in niverjetno, da bi zaviralci encimovCYP450vplivalinanjegovokoncentracijo.Odpresnovkov v obtoku je večina glukuronidnihkonjugatov posakonazola, opazili pa so le majhne količine oksidativnih presnovkov
altered medicine levels, blood phosphorus decreased, chest x-ray abnormal * Based on adverse reactions observed with the oral suspension, gastro-resistant tablets, and concentrate for solution for infusion. 
*Na podlagi neželenih učinkov, opaženih s peroralno suspenzijo, gastrorezistentnimi tabletami in koncentratom za raztopino za infundiranje.
The AUC of posaconazole is: 4 times greater when administered with a high fat meal (~ 50 grams fat) and about 2.6 times greater when administered during a non-fat meal or nutritional supplement (14 grams fat) relative to the fasted state (see sections 4.2 and 4.5). 
2,6-kratvečjaprizaužitju z nemastnimobrokomali s prehranskimdodatkom(14gramovmaščobe)vprimerjavi s stanjem na tešče (glejte poglavji 4.2 in 4.5).
In a study of 136 neutropenic paediatric patients 11 months - 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the pre-specified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL). 
zdravljenih s peroralno suspenzijo posakonazola v odmerkih do 18 mg/kg/dan,razdeljenih na tri odmerke dnevno, je približno 50 % bolnikov doseglo vnaprej določen cilj (Cav7.
Posaconazole AHCL may possibly increase the risk of side effects of some other medicines by increasing the amount of these medicines in the blood. 
Zdravilo Posakonazol AHCL lahko poveča koncentracijo naslednjih zdravil v krvi, to pa lahko povzroči zelo resne motnje srčnega ritma:
Efavirenz (400 mg once a day) decreased the Cmax and AUC of posaconazole by 45 % and 50 %, respectively. 
Efavirenz(400 mg enkrat na dan) je zmanjšalCmaxposakonazolaza 45 %, njegovoAUC paza 50 %.Sočasni uporabi posakonazola in efavirenza se je treba izogibati, razen če korist za bolnika odtehtatveganje.
Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk (see section 
Zato se je treba izogibati njihovi sočasni uporabi s posakonazolom, razen če korist za bolnika odtehta tveganje (glejte poglavje 4.5).
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA
Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly. 
Koncentracijosirolimusa jetrebaizmeritiob uvedbi zdravljenja, med sočasno uporabo in tudi obukinitvi zdravljenja s posakonazolom in po potrebi ustrezno prilagoditiodmerke sirolimusa.Zavedatisejetreba, da se med sočasno uporabo sirolimusa in posakonazola spremeni razmerje med najnižjokoncentracijo sirolimusa in njegovo AUC.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of oral suspension contains 40 mg of posaconazole. 
Učinkovina je posakonazol.En mililiter peroralne suspenzije vsebuje40 miligramovposakonazola.
In healthy volunteers under fasting conditions, dividing the total daily dose (800 mg) into 200 mg four times daily compared to 400 mg twice daily, was shown to increase posaconazole exposure by 2.6-fold. 
Pri zdravih prostovoljcih na tešče sopokazali,darazdelitevcelotnegadnevnegaodmerka(800mg) na 200mgštirikratnadan v primerjavis
Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients: - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. 
- bolnikih, ki prejemajo kemoterapijo za doseganje remisije akutne mieloične levkemije (AML) ali mielodisplastičnih sindromov (MDS) in pri katerih se zato pričakuje dolgotrajnejša nevtropenija ter imajo veliko tveganje za invazivne glivne okužbe,
Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies. 
AUC za 358 %.Vštudijah klinične učinkovitosti so poročali o klinično pomembnihinterakcijah, ki so zahtevale sprejem v bolnišnico in/ali ukinitev posakonazola.
Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the 
Vštudijiprizdravihprostovoljcihje peroralnasuspenzija posakonazola (200 mg enkrat na dan10 dni)
Posaconazole oral suspension 
Peroralna suspenzijaposakonaz l
OTHER SPECIAL WARNING(S), IF NECESSARY Posaconazole oral suspension and posaconazole tablets are NOT interchangeable. 
Peroralna suspenzija posakonazola NI medsebojno zamenljiva s tabletami posakonazola.
Each dose of Posaconazole AHCL should be administered during or immediately after a meal, or a nutritional supplement in patients who cannot tolerate food to enhance the oral absorption and to ensure adequate exposure 
Bolniki, ki ne prenašajo hrane, naj zdravilo vzamejomed alitakoj po zaužitju prehranskega dodatka, da bi povečali peroralno absorpcijo in zagotovili zadostno izpostavljenost
high or low blood pressure - low blood pressure - inflammation of the pancreas (pancreatitis) - this may cause severe stomach pain - oxygen supply to the spleen is interrupted (splenic infarction) - this may cause severe stomach pain - severe kidney problems - signs include passing more or less urine, that is a different colour than usual - high blood levels of creatinine - shown in blood tests - cough, hiccups - nose bleeds - severe sharp chest pain when breathing in (pleurritic pain) - swelling of lymph glands (lymphadenopathy) - reduced feeling of sensitivity especially on the skin - tremor - high or low blood sugar levels - blurred vision, sensitivity to light - hair loss (alopecia) - mouth ulcers - shivering, feeling generally unwell - pain, back or neck pain, pain in arms or legs - water retention (oedema) - menstrual problems (abnormal vaginal bleeding) - inability to sleep (insomnia) - being completely or partially unable to talk - swelling of the mouth - abnormal dreams, or difficulty sleeping - problems with co-ordination or balance - mucosal inflammation - stuffy nose - difficulty breathing - chest discomfort - feeling bloated - mild to severe nausea, vomiting, cramps and diarrhoea, usually caused by a virus, stomach pain - belching - feeling jittery 
- prekinitev preskrbe vranice s kisikom (vranični infarkt) - povzročilahkohudebolečine v trebuhu - hude težave zledvicami - med znaki so izločanje več ali manj urina, ki je drugačne barve kot po navadi - visoka koncentracija kreatinina v krvi - pokaže se na preiskavah krvi - kašelj, kolcanje - krvavitve iz nosu
When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose). 
odmerekciklosporina zmanjšati (npr.napribližnotričetrtine trenutnega odmerka).
Discontinuation of Posaconazole AHCL should be considered if clinical signs and symptoms are consistent with development of liver disease. 
Zdravilo Posakonazol AHCL peroralna suspenzija je indicirano tudi za profilakso invazivnih glivnih okužb pri: